MCID: SBS003
MIFTS: 48

Substance Abuse malady

Summaries for Substance Abuse

About this section


Disease Ontology:10 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary: Substance Abuse, also known as substance abuse problem, is related to personality disorder and antisocial personality disorder. An important gene associated with Substance Abuse is SLC6A2 (solute carrier family 6 (neurotransmitter transporter), member 2), and among its related pathways are Histidine metabolism and Tyrosine metabolism p.1 dopamine . The compounds (r)-(-)-deprenyl hydrochloride and phenethylamine, have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related mouse phenotypes are nervous system and behavior/neurological.

Wikipedia:65 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Aliases & Classifications for Substance Abuse

About this section

Substance Abuse, Aliases & Descriptions:

Name: Substance Abuse 10 12 4
 
Substance Abuse Problem 62


External Ids:

Disease Ontology10 DOID:302
NCIt40 C16522
SNOMED-CT57 66214007, 26416006
MeSH35 D019966
ICD9CM29 305

Related Diseases for Substance Abuse

About this section

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 76)
idRelated DiseaseScoreTop Affiliating Genes
1personality disorder31.1HTR1B, MAOA, MAOB
2antisocial personality disorder31.1MAOA, HTR1B
3conduct disorder30.9MAOA, DRD5
4schizophrenia30.9HTR1B, MAOA, MAOB, DRD5, TDO2, SLC6A2
5bipolar disorder30.7MAOA, MAOB, DRD5, SLC6A2
6anxiety disorder30.7MAOA
7mood disorder30.6HTR1B, MAOA, MAOB, SLC6A2
8generalized anxiety disorder30.4MAOA, SLC6A2
9borderline personality disorder30.3MAOA, HTR1B
10obesity30.3SLC6A2, MAOB, MAOA
11attention deficit-hyperactivity disorder30.3HTR1B, MAOA, DRD5, SLC6A2
12panic disorder30.1SLC6A2, MAOA
13anorexia nervosa30.1SLC6A2, MAOA
14bulimia nervosa30.1MAOA, HTR1B
15alcohol dependence30.1MAOA, HTR1B, ADH4
16hepatitis10.5
17alcohol abuse10.5
18drug addiction10.4
19hepatitis c10.4
20cocaine abuse10.3
21pathological gambling10.3
22dementia10.3
23opioid dependence10.2
24cannabis abuse10.2
25opioid abuse10.2
26fetal alcohol syndrome10.2
27eating disorder10.2
28substance dependence10.2
29developmental disabilities10.2
30asthma10.1
31hepatitis c virus10.1
32huntington disease10.1
33hiv-110.1
34brain injury10.1
35hepatitis b10.1
36liver disease10.1
37traumatic brain injury10.1
38avoidant personality disorder10.1
39multiple personality disorder10.1
40phencyclidine abuse10.1
41amphetamine abuse10.1
42antidepressant type abuse10.1
43polyhydramnios10.1
44barbiturate abuse10.1
45post-traumatic stress disorder10.1
46hepatitis d10.1
47hypercalcemia10.1
48hallucinogen abuse10.1
49cerebritis10.1
50gastroschisis10.1

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to substance abuse

Symptoms for Substance Abuse

About this section

Drugs & Therapeutics for Substance Abuse

About this section

Drug clinical trials:

Search ClinicalTrials for Substance Abuse

Search NIH Clinical Center for Substance Abuse

Genetic Tests for Substance Abuse

About this section

Anatomical Context for Substance Abuse

About this section

MalaCards organs/tissues related to Substance Abuse:

33
Testes, Brain, Liver, Heart, Kidney, Hypothalamus, Pituitary, Subthalamic nucleus

Animal Models for Substance Abuse or affiliated genes

About this section

MGI Mouse Phenotypes related to Substance Abuse:

37
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036318.1MAOB, DRD5, TDO2, SLC6A2, MAOA
2MP:00053867.5SLC6A2, TDO2, MAOB, MAOA, HTR1B

Publications for Substance Abuse

About this section

Articles related to Substance Abuse:

(show top 50)    (show all 599)
idTitleAuthorsYear
1
Does a history of substance abuse and illness chronicity predict increased impulsivity in bipolar disorder? (25863910)
2015
2
Accuracy of popular media reporting on tobacco cessation therapy in substance abuse and mental health populations. (25814498)
2015
3
Treating substance abuse is not enough: Comorbidities in consecutively admitted female prisoners. (25770695)
2015
4
Service utilization of asians and other racial-ethnic groups: comparisons in a state substance abuse treatment system. (24093520)
2014
5
Substance Abuse, Violence, and HIV/AIDS (SAVA) Syndemic Effects on Viral Suppression Among HIV Positive Women of Color. (25397666)
2014
6
Criminal justice outcomes after engagement in outpatient substance abuse treatment. (24238717)
2014
7
The tangled branches (las ramas enredadas): sexual risk, substance abuse, and intimate partner violence among Hispanic men who have sex with men. (24084703)
2014
8
Referral for substance abuse treatment and depression improvement among patients with co-occurring disorders seeking behavioral health services in primary care. (24095002)
2014
9
The Relationship of State Medicaid Coverage to Medicaid Acceptance Among Substance Abuse Providers in the United States. (24407938)
2014
10
Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. (25291977)
2014
11
A review of existing treatments for substance abuse among the elderly and recommendations for future directions. (23471422)
2013
12
How the states stack up: disparities in substance abuse outpatient treatment completion rates for minorities. (23664124)
2013
13
Approaches to substance abuse in Cuba: Ricardo A. GonzA!lez MD PhD DrSc. Psychiatrist and consulting professor, Eduardo B. Ordaz. Psychiatric Hospital, Havana. Interviewed by Christina Mills. (24253343)
2013
14
Utilization of communication technology by patients enrolled in substance abuse treatment. (23107600)
2013
15
Substance abuse journal: new beginnings. (24159902)
2013
16
Future research needs for evaluating the integration of mental health and substance abuse treatment with primary care. (24042241)
2013
17
Substance use among women receiving post-rape medical care, associated post-assault concerns and current substance abuse: results from a national telephone household probability sample. (23380490)
2013
18
Work needed to close gaps in coverage for mental health, substance abuse treatment. (24386795)
2013
19
Does Substance Abuse Fall Exclusively Along the Externalizing Spectrum? (24328838)
2013
20
The provider perception inventory: psychometrics of a scale designed to measure provider stigma about HIV, substance abuse, and MSM behavior. (23082899)
2013
21
Gene-environment correlation in the development of adolescent substance abuse: selection effects of child personality and mediation via contextual risk factors. (23398757)
2013
22
Employment status of veterans receiving substance abuse treatment from the U.S. Department of Veterans Affairs. (23370624)
2013
23
Predictors of retention in a drug-free unit/substance abuse treatment in prison. (23706657)
2013
24
Substance screening and referral for substance abuse treatment in an integrated mental health care program. (23280462)
2013
25
Comment on: pilot evaluation of a substance abuse prevention group intervention for at-risk bariatric surgery candidates. (23477955)
2013
26
Substance abuse as a risk factor for violence in mental illness: some implications for forensic psychiatric practice and clinical ethics. (23722099)
2013
27
Substance Abuse Treatment, HIV/AIDS, and the Continuum of Response for People Who Inject Drugs. (23243517)
2012
28
Depression as a mediator of the association between substance abuse and negative parenting of fathers. (22243417)
2012
29
Affective Awareness in Parenting of Fathers with Co-Occurring Substance Abuse and Intimate Partner Violence. (23710257)
2012
30
Organizational consequences of staff turnover in outpatient substance abuse treatment programs. (22154028)
2012
31
Changing pattern of substance abuse in patients attending a de-addiction centre in north India (1978-2008). (22825602)
2012
32
Substance abuse among migrant workers of Thai-Laos border, Thailand. (23140041)
2012
33
Community capacity assessment in preventing substance abuse: a participatory approach. (23193506)
2012
34
How to measure outcome in clinical trials of substance abuse treatment. (22372699)
2012
35
Culturally competent substance abuse treatment with transgender persons. (22873185)
2012
36
Substance abuse and movement disorders: complex interactions and comorbidities. (23030352)
2012
37
The dangers of substance abuse in adolescents with chronic kidney disease: a review of the literature. (22558679)
2012
38
A snapshot of North Carolina's public mental health, developmental disabilities, and substance abuse service system. (22779165)
2012
39
Disparities in completion of substance abuse treatment among Latino subgroups in Los Angeles County, CA. (22658303)
2012
40
Chronic illness histories of adults entering treatment for co-occurring substance abuse and other mental health disorders. (22211340)
2012
41
Resources and training in outpatient substance abuse treatment facilities. (22154031)
2012
42
Relationship of substance abuse to dependence in the U.S. general population. (22456242)
2012
43
Models of neurological disease (substance abuse): self-administration in monkeys. (22382996)
2011
44
Increasing ethnic minority participation in substance abuse clinical trials: lessons learned in the National Institute on Drug Abuse's Clinical Trials Network. (21988575)
2011
45
Editors' introduction: Identifying and assessing promising practices for criminal justice clients--California Substance Abuse Research Consortium (SARC) meetings, 2010. (22185034)
2011
46
Gender differences and conduct disorder among American Indian adolescents in substance abuse treatment. (12733762)
2003
47
Diagnosing antisocial personality disorder among substance abusers: the scid versus the MCMI-II. (11727884)
2001
48
A functionally deficient DRD2 variant [Ser311Cys] is not linked to alcoholism and substance abuse. (9650635)
1998
49
Substance abuse vulnerability and D2 receptor genes. (7681236)
1993
50
The antecedents of women's crack cocaine abuse: family substance abuse, sexual abuse, depression and illicit drug use. (8246316)
1993

Variations for Substance Abuse

About this section

Expression for genes affiliated with Substance Abuse

About this section

Search GEO for disease gene expression data for Substance Abuse.

Pathways for genes affiliated with Substance Abuse

About this section

Pathways related to Substance Abuse according to GeneCards/GeneDecks:

(show all 19)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
histamine biosynthesis38
9.6MAOA, MAOB
29.6MAOB, MAOA
3
Show member pathways
choline degradation I38
glycine biosynthesis III38
serine and glycine biosynthesis38
glycine betaine degradation38
glycine biosynthesis38
9.6MAOB, MAOA
4
Show member pathways
citrulline-nitric oxide cycle38
arginine degradation I (arginase pathway)38
proline degradation38
glutamine degradation I38
proline biosynthesis I38
superpathway of citrulline metabolism38
proline biosynthesis II (from arginine)38
citrulline biosynthesis38
arginine degradation VI (arginase 2 pathway)38
Urea cycle and metabolism of amino groups38
asparagine biosynthesis I38
4-hydroxyproline degradation I38
citrulline degradation38
9.6MAOB, MAOA
5
Show member pathways
9.6MAOB, MAOA
69.6MAOA, MAOB
79.6MAOB, MAOA
89.6MAOB, MAOA
99.2HTR1B, MAOA
10
Show member pathways
9.1HTR1B, DRD5
11
Show member pathways
phenylalanine utilization38
noradrenaline and adrenaline degradation38
phenylalanine degradation IV38
9.1MAOB, MAOA, ADH4
12
Show member pathways
9.1ADH4, MAOB, MAOA
13
Show member pathways
9.1MAOB, ADH4, MAOA
14
Show member pathways
9.1MAOB, ADH4, MAOA
15
Show member pathways
Serotonin Transporter Activity38
9.1SLC6A2, TDO2, MAOA
16
Show member pathways
tryptophan degradation X (mammalian, via tryptamine)38
2-amino-3-carboxymuconate semialdehyde degradation to glutaryl-CoA38
tryptophan degradation38
glutaryl-CoA degradation38
serotonin degradation38
NAD de novo biosynthesis38
superpathway of melatonin degradation38
tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde38
tryptophan utilization I38
melatonin degradation I38
9.0MAOA, MAOB, TDO2
17
Show member pathways
9.0MAOB, TDO2, MAOA
18
Show member pathways
8.5TDO2, MAOB, MAOA, ADH4
19
Show member pathways
8.3HTR1B, MAOA, MAOB, DRD5

Compounds for genes affiliated with Substance Abuse

About this section

Compounds related to Substance Abuse according to GeneCards/GeneDecks:

(show top 50)    (show all 151)
idCompoundScoreTop Affiliating Genes
1(r)-(-)-deprenyl hydrochloride6110.0MAOA, MAOB
2phenethylamine,4510.0MAOA, MAOB
3brofaromine4510.0MAOA, MAOB
4pirlindole459.9MAOA, MAOB
51-methyl-4-phenyl-2,3-dihydropyridinium459.9MAOA, MAOB
6toloxatone459.9MAOA, MAOB
7pyrazoline459.9MAOA, MAOB
8bifemelane hydrochloride619.9MAOB, MAOA
94,6-Dihydroxyquinoline269.9MAOA, MAOB
10isocarboxazid45 1310.9MAOA, MAOB
11iproniazid45 1310.9MAOB, MAOA
12rasagiline mesylate619.9MAOA, MAOB
13lazabemide hydrochloride619.9MAOA, MAOB
141,4-diphenyl-2-butene459.8MAOA, MAOB
15lazabemide459.8MAOB, MAOA
16m-tyramine459.7MAOA, MAOB, SLC6A2
17p-chloroamphetamine459.7MAOA, SLC6A2, MAOB
18nomifensine45 30 1311.7MAOA, SLC6A2, MAOB
19phentermine45 1310.7MAOA, SLC6A2, MAOB
20d amphetamine459.7MAOB, MAOA, SLC6A2
21mdma459.7MAOA, MAOB, SLC6A2
22mhpg459.7MAOA, SLC6A2, MAOB
23homovanillic acid45 2610.6MAOB, MAOA, SLC6A2
241 methyl 4 phenylpyridinium459.6SLC6A2, MAOA, MAOB
25sertraline45 30 51 26 1313.6SLC6A2, MAOA, MAOB
265-hydroxyindoleacetic acid45 2610.6SLC6A2, MAOB, MAOA
27tyramine45 30 2611.6SLC6A2, MAOB, MAOA
28harman459.6MAOB, MAOA
29amitriptyline45 30 51 1312.6MAOA, SLC6A2, MAOB
30methamphetamine45 51 1311.4MAOA, MAOB, SLC6A2
316-hydroxydopamine459.4MAOA, SLC6A2, MAOB
32amphetamine45 51 1311.3SLC6A2, MAOB, MAOA
33milacemide459.3MAOB, MAOA
34citalopram45 51 26 1312.3MAOB, SLC6A2, MAOA
35clomipramine45 51 1311.2HTR1B, SLC6A2, MAOA
36paroxetine45 51 30 1312.2SLC6A2, HTR1B, MAOA
37mptp459.2MAOA, MAOB, SLC6A2
38tryptamine45 30 2611.2MAOB, HTR1B, MAOA
39Serotonin269.2MAOA, MAOB, HTR1B
40methylphenidate45 51 1311.2MAOB, SLC6A2, DRD5, MAOA
41catecholamine459.1MAOB, DRD5, SLC6A2, MAOA
42ropinirole45 1310.1DRD5, HTR1B, MAOB
43apomorphine30 45 1311.0MAOB, HTR1B, DRD5
44maoa458.9MAOB, MAOA, HTR1B, SLC6A2
45fluoxetine45 51 30 1311.9SLC6A2, MAOB, HTR1B, MAOA
46amine458.8MAOA, SLC6A2, MAOB, HTR1B
47levodopa45 139.7MAOA, HTR1B, MAOB, DRD5
48norepinephrine45 26 1310.6DRD5, SLC6A2, MAOB, MAOA
49dopamine45 30 26 1311.3HTR1B, MAOA, SLC6A2, DRD5, MAOB
505-hydroxytryptamine458.2HTR1B, MAOB, TDO2, SLC6A2, MAOA

GO Terms for genes affiliated with Substance Abuse

About this section

Biological processes related to Substance Abuse according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1negative regulation of serotonin secretionGO:00140639.3HTR1B, MAOB
2response to ethanolGO:00454719.2MAOB, HTR1B
3xenobiotic metabolic processGO:00068059.1MAOB, ADH4, MAOA
4response to cocaineGO:00422209.0DRD5, HTR1B
5synaptic transmissionGO:00072688.4SLC6A2, DRD5, MAOA, HTR1B
6small molecule metabolic processGO:00442818.2ADH4, MAOA, MAOB, TDO2

Molecular functions related to Substance Abuse according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1primary amine oxidase activityGO:00081319.6MAOB, MAOA

Products for genes affiliated with Substance Abuse

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Substance Abuse

About this section
4CDC
15ExPASy
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
52PubMed
53QIAGEN
58SNOMED-CT via Orphanet
62UMLS
63UMLS via Orphanet